---
title: ctDNA in Cutaneous Squamous Cell Carcinoma
nct_id: NCT06875609
overall_status: RECRUITING
sponsor: Massachusetts Eye and Ear Infirmary
study_type: OBSERVATIONAL
primary_condition: Cutaneous Squamous Cell Carcinoma
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06875609.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06875609"
ct_last_update_post_date: 2026-03-30
last_seen_at: "2026-05-12T07:23:33.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# ctDNA in Cutaneous Squamous Cell Carcinoma

**Official Title:** ctDNA Clearance and ctDNA Monitoring Study in Cutaneous Squamous Cell Carcinoma

**NCT ID:** [NCT06875609](https://clinicaltrials.gov/study/NCT06875609)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Massachusetts Eye and Ear Infirmary
- **Collaborators:** Haystack Oncology, Inc., Massachusetts General Hospital
- **Conditions:** Cutaneous Squamous Cell Carcinoma
- **Start Date:** 2025-03-24
- **Completion Date:** 2029-04-30
- **CT.gov Last Update:** 2026-03-30

## Brief Summary

The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.

## Detailed Description

The study aims to better understand whether circulating tumor DNA, or ctDNA, a type of personalized blood test informed by the tumor, can help monitor recurrence and treatment responses in patients with cutaneous squamous cell carcinoma (CSCC), especially during and after treatment. Blood samples will be collected during regular treatment visits or through mobile phlebotomy visits, and analyzed to study how ctDNA levels change over time. Participants will be in the study for 2 years.

Circulating tumor DNA consists of small fragments of DNA shed into the bloodstream by cancer cells. It may serve as a non-invasive biomarker for detecting and monitoring CSCC, offering insights into tumor treatment response and/or progression. ctDNA can provide a "liquid biopsy," allowing real-time tracking of tumor dynamics. Specifically, the study is researching how ctDNA levels change in patients undergoing surgery, immunotherapy, or other standard treatments. The goal is to see if ctDNA can serve as a biomarker to better understand treatment response and detect potential progression/ recurrence of the cancer.

This study does not involve any experimental drugs or devices. All drugs and treatments administered to participants, including surgery and immunotherapy, are part of standard of care. The ctDNA blood test is being used as a research tool and is not currently approved by the U.S. Food and Drug Administration (FDA) for monitoring CSCC. The study aims to evaluate its potential future use as a reliable biomarker.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Post-Operative Cohort

Inclusion Criteria:

* Patients with surgically resectable primary CSCC with PNI (\>0.1mm caliber nerve) or at least 2 high-risk features defined as size \> 2cm, recurrent CSCC, LVI, immunosuppressed, poorly differentiated, and/or invasion \>6mm/beyond subcutaneous fat;
* Patients with surgically resectable regional metastases not receiving neoadjuvant therapy

Exclusion Criteria:

* Patients with Cutaneous Squamous Cell Carcinoma not amenable to surgical resection
* Patients receiving or undergoing systemic therapies.

Neoadjuvant Cohort

Inclusion Criteria:

* Patients with resectable AJCC (8th ed) Stage II, III or IV(M0) CSCC treated with neoadjuvant immunotherapy as part of standard care.

Exclusion Criteria:

* Patients ineligible for neoadjuvant treatment.

Definitive Immunotherapy Cohort

Inclusion Criteria:

* Patients with unresectable locally advanced or metastatic CSCC, AJCC (8th ed) Stage II, III, or IV), receiving immunotherapy as part of standard of care.

Exclusion Criteria:

* Patients undergoing systemic therapies outside the standard of care or enrolled in conflicting clinical trials.
```

## Arms

- **Post-Operative Cohort** — Cutaneous Squamous Cell Carcinoma cancer patients treated with surgery.
- **Neoadjuvant Cohort** — Cutaneous Squamous Cell Carcinoma patients treated with Neoadjuvant immunotherapy.
- **Definitive Immunotherapy Cohort** — Cutaneous Squamous Cell Carcinoma patients treated with definitive immunotherapy.

## Interventions

- **Blood and Tissue Collection** (DIAGNOSTIC_TEST) — Blood samples, and tissue samples will be collected from the participants, and used to determine whether circulating tumor DNA (ctDNA) testing can help monitor treatment in patients with CSCC, and to determine how ctDNA levels change in patients.

## Primary Outcomes

- **2-year recurrence-free survival (RFS) in patients with detectable vs no detectable ctDNA after surgery** _(time frame: 24 Months)_ — To determine if there is an association between ctDNA clearance (defined as no detection of ctDNA) after surgical intervention and 2-year recurrence-free survival (RFS). The outcome will measure both ctDNA clearance (as a binary variable: detection or no detection) and RFS (measured in months). The association between these two outcomes will be analyzed as the primary outcome to determine if no detection of ctDNA is associated with longer RFS.
- **Neoadjuvant Cohort Primary Outcome: Response Monitoring** _(time frame: 24 Months)_ — To evaluate ctDNA as a biomarker of response to neoadjuvant immunotherapy.
- **Definitive Treatment Cohort Primary Outcome** _(time frame: 24 Months)_ — To evaluate whether ctDNA correlates with response to immunotherapy.

## Secondary Outcomes

- **Post-Operative Cohort Secondary Outcome: Residual Free Survival (RFS) Surveillance over 2 Year** _(time frame: 24 Months)_
- **Neoadjuvant Cohort Secondary Outcome: Correlation with Pathological Response** _(time frame: 24 Months)_

## Locations (1)

- Massachusetts Eye and Ear, Boston, Massachusetts, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.massachusetts eye and ear|boston|massachusetts|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06875609.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06875609*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*